Hyperpolypharmacy and Frailty in Kidney Transplant Recipients

Kidney transplant recipients (KTRs) take multiple medications including immunosuppressants every day. Although polypharmacy is associated with frailty, the situation remains unknown in KTRs. The aim of the present study is to investigate the association between hyperpolypharmacy and frailty in KTRs....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Transplantation proceedings 2022-03, Vol.54 (2), p.367-373
Hauptverfasser: Kosoku, Akihiro, Iwai, Tomoaki, Kabei, Kazuya, Nishide, Shunji, Maeda, Keiko, Kumada, Norihiko, Uchida, Junji
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 373
container_issue 2
container_start_page 367
container_title Transplantation proceedings
container_volume 54
creator Kosoku, Akihiro
Iwai, Tomoaki
Kabei, Kazuya
Nishide, Shunji
Maeda, Keiko
Kumada, Norihiko
Uchida, Junji
description Kidney transplant recipients (KTRs) take multiple medications including immunosuppressants every day. Although polypharmacy is associated with frailty, the situation remains unknown in KTRs. The aim of the present study is to investigate the association between hyperpolypharmacy and frailty in KTRs. This study was a single-center, cross-sectional investigation carried out on KTRs between August 2018 and February 2019 at Osaka City University Hospital. Frailty was evaluated using the Kihon Checklist (KCL). The number of medications was determined from the regular medicines the participants took by mouth every day. Hyperpolypharmacy was defined as 10 or more medications. Statistical analyses were performed using multivariable logistic regression analyses and multivariable linear regression analyses. Of 211 KTRs enrolled in this study, the mean (SD) number of medicines taken orally regularly was 9.4 (3.4), and hyperpolypharmacy participants accounted for 41%. Hyperpolypharmacy was associated with both the total KCL score (odds ratio, 1.13; P = .016) and being frail compared with being robust (odds ratio, 5.70; P = .007) after adjustments for age, sex, and body mass index. The number of medications was associated with both the total KCL score (β = 0.20; P < .001) and being frail compared with being robust (β = 2.51; P < .001) after adjustments for age, sex, body mass index, dialysis vintage, time after transplant, serum albumin, and estimated glomerular filtration rate. The optimal cutoff value for the number of medications to detect frailty was 12 (area under the curve, 0.81). In KTRs, hyperpolypharmacy was prevalent and was associated with frailty.
doi_str_mv 10.1016/j.transproceed.2021.11.026
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2620753493</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0041134521009325</els_id><sourcerecordid>2620753493</sourcerecordid><originalsourceid>FETCH-LOGICAL-c498t-f6a33602b8a78c1687756e4be66083e2dd02051ff7a328b5274c0d02c7b70aa43</originalsourceid><addsrcrecordid>eNqNkNFLwzAQxoMobk7_BSk--dJ6SdqkE3yQ6VQcCDKfQ5peMaNra9IJ_e_N3AY--nTc5bv78v0IuaKQUKDiZpX0Tje-c61BLBMGjCaUJsDEERnTXPKYCcaPyRggpTHlaTYiZ96vIPQs5adkxDPgnAs5JnfPQ4eua-uh-9Rurc0Q6aaM5k7buh8i20SvtmxwiJa_lrVu-ugdje0sNr0_JyeVrj1e7OuEfMwfl7PnePH29DK7X8QmneZ9XAkd3IAVuZa5oSKXMhOYFigE5BxZWQKDjFaV1JzlRcZkaiDMjCwkaJ3yCbne3Q2Zvzboe7W23mAdvoPtxquQF2TG0ykP0tud1LjWe4eV6pxdazcoCmqLT63UX3xqi09RqgK-sHy599kU6_B2WD3wCoKHnQBD2m-LTnkTSBgsrUPTq7K1__H5Aa0Dh38</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2620753493</pqid></control><display><type>article</type><title>Hyperpolypharmacy and Frailty in Kidney Transplant Recipients</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Kosoku, Akihiro ; Iwai, Tomoaki ; Kabei, Kazuya ; Nishide, Shunji ; Maeda, Keiko ; Kumada, Norihiko ; Uchida, Junji</creator><creatorcontrib>Kosoku, Akihiro ; Iwai, Tomoaki ; Kabei, Kazuya ; Nishide, Shunji ; Maeda, Keiko ; Kumada, Norihiko ; Uchida, Junji</creatorcontrib><description>Kidney transplant recipients (KTRs) take multiple medications including immunosuppressants every day. Although polypharmacy is associated with frailty, the situation remains unknown in KTRs. The aim of the present study is to investigate the association between hyperpolypharmacy and frailty in KTRs. This study was a single-center, cross-sectional investigation carried out on KTRs between August 2018 and February 2019 at Osaka City University Hospital. Frailty was evaluated using the Kihon Checklist (KCL). The number of medications was determined from the regular medicines the participants took by mouth every day. Hyperpolypharmacy was defined as 10 or more medications. Statistical analyses were performed using multivariable logistic regression analyses and multivariable linear regression analyses. Of 211 KTRs enrolled in this study, the mean (SD) number of medicines taken orally regularly was 9.4 (3.4), and hyperpolypharmacy participants accounted for 41%. Hyperpolypharmacy was associated with both the total KCL score (odds ratio, 1.13; P = .016) and being frail compared with being robust (odds ratio, 5.70; P = .007) after adjustments for age, sex, and body mass index. The number of medications was associated with both the total KCL score (β = 0.20; P &lt; .001) and being frail compared with being robust (β = 2.51; P &lt; .001) after adjustments for age, sex, body mass index, dialysis vintage, time after transplant, serum albumin, and estimated glomerular filtration rate. The optimal cutoff value for the number of medications to detect frailty was 12 (area under the curve, 0.81). In KTRs, hyperpolypharmacy was prevalent and was associated with frailty.</description><identifier>ISSN: 0041-1345</identifier><identifier>EISSN: 1873-2623</identifier><identifier>DOI: 10.1016/j.transproceed.2021.11.026</identifier><identifier>PMID: 35033367</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Cross-Sectional Studies ; Frailty - diagnosis ; Humans ; Kidney Transplantation - adverse effects ; Polypharmacy ; Renal Dialysis ; Transplant Recipients</subject><ispartof>Transplantation proceedings, 2022-03, Vol.54 (2), p.367-373</ispartof><rights>2021 The Author(s)</rights><rights>Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c498t-f6a33602b8a78c1687756e4be66083e2dd02051ff7a328b5274c0d02c7b70aa43</citedby><cites>FETCH-LOGICAL-c498t-f6a33602b8a78c1687756e4be66083e2dd02051ff7a328b5274c0d02c7b70aa43</cites><orcidid>0000-0003-0245-2994</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0041134521009325$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35033367$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kosoku, Akihiro</creatorcontrib><creatorcontrib>Iwai, Tomoaki</creatorcontrib><creatorcontrib>Kabei, Kazuya</creatorcontrib><creatorcontrib>Nishide, Shunji</creatorcontrib><creatorcontrib>Maeda, Keiko</creatorcontrib><creatorcontrib>Kumada, Norihiko</creatorcontrib><creatorcontrib>Uchida, Junji</creatorcontrib><title>Hyperpolypharmacy and Frailty in Kidney Transplant Recipients</title><title>Transplantation proceedings</title><addtitle>Transplant Proc</addtitle><description>Kidney transplant recipients (KTRs) take multiple medications including immunosuppressants every day. Although polypharmacy is associated with frailty, the situation remains unknown in KTRs. The aim of the present study is to investigate the association between hyperpolypharmacy and frailty in KTRs. This study was a single-center, cross-sectional investigation carried out on KTRs between August 2018 and February 2019 at Osaka City University Hospital. Frailty was evaluated using the Kihon Checklist (KCL). The number of medications was determined from the regular medicines the participants took by mouth every day. Hyperpolypharmacy was defined as 10 or more medications. Statistical analyses were performed using multivariable logistic regression analyses and multivariable linear regression analyses. Of 211 KTRs enrolled in this study, the mean (SD) number of medicines taken orally regularly was 9.4 (3.4), and hyperpolypharmacy participants accounted for 41%. Hyperpolypharmacy was associated with both the total KCL score (odds ratio, 1.13; P = .016) and being frail compared with being robust (odds ratio, 5.70; P = .007) after adjustments for age, sex, and body mass index. The number of medications was associated with both the total KCL score (β = 0.20; P &lt; .001) and being frail compared with being robust (β = 2.51; P &lt; .001) after adjustments for age, sex, body mass index, dialysis vintage, time after transplant, serum albumin, and estimated glomerular filtration rate. The optimal cutoff value for the number of medications to detect frailty was 12 (area under the curve, 0.81). In KTRs, hyperpolypharmacy was prevalent and was associated with frailty.</description><subject>Cross-Sectional Studies</subject><subject>Frailty - diagnosis</subject><subject>Humans</subject><subject>Kidney Transplantation - adverse effects</subject><subject>Polypharmacy</subject><subject>Renal Dialysis</subject><subject>Transplant Recipients</subject><issn>0041-1345</issn><issn>1873-2623</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkNFLwzAQxoMobk7_BSk--dJ6SdqkE3yQ6VQcCDKfQ5peMaNra9IJ_e_N3AY--nTc5bv78v0IuaKQUKDiZpX0Tje-c61BLBMGjCaUJsDEERnTXPKYCcaPyRggpTHlaTYiZ96vIPQs5adkxDPgnAs5JnfPQ4eua-uh-9Rurc0Q6aaM5k7buh8i20SvtmxwiJa_lrVu-ugdje0sNr0_JyeVrj1e7OuEfMwfl7PnePH29DK7X8QmneZ9XAkd3IAVuZa5oSKXMhOYFigE5BxZWQKDjFaV1JzlRcZkaiDMjCwkaJ3yCbne3Q2Zvzboe7W23mAdvoPtxquQF2TG0ykP0tud1LjWe4eV6pxdazcoCmqLT63UX3xqi09RqgK-sHy599kU6_B2WD3wCoKHnQBD2m-LTnkTSBgsrUPTq7K1__H5Aa0Dh38</recordid><startdate>202203</startdate><enddate>202203</enddate><creator>Kosoku, Akihiro</creator><creator>Iwai, Tomoaki</creator><creator>Kabei, Kazuya</creator><creator>Nishide, Shunji</creator><creator>Maeda, Keiko</creator><creator>Kumada, Norihiko</creator><creator>Uchida, Junji</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0245-2994</orcidid></search><sort><creationdate>202203</creationdate><title>Hyperpolypharmacy and Frailty in Kidney Transplant Recipients</title><author>Kosoku, Akihiro ; Iwai, Tomoaki ; Kabei, Kazuya ; Nishide, Shunji ; Maeda, Keiko ; Kumada, Norihiko ; Uchida, Junji</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c498t-f6a33602b8a78c1687756e4be66083e2dd02051ff7a328b5274c0d02c7b70aa43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Cross-Sectional Studies</topic><topic>Frailty - diagnosis</topic><topic>Humans</topic><topic>Kidney Transplantation - adverse effects</topic><topic>Polypharmacy</topic><topic>Renal Dialysis</topic><topic>Transplant Recipients</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kosoku, Akihiro</creatorcontrib><creatorcontrib>Iwai, Tomoaki</creatorcontrib><creatorcontrib>Kabei, Kazuya</creatorcontrib><creatorcontrib>Nishide, Shunji</creatorcontrib><creatorcontrib>Maeda, Keiko</creatorcontrib><creatorcontrib>Kumada, Norihiko</creatorcontrib><creatorcontrib>Uchida, Junji</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Transplantation proceedings</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kosoku, Akihiro</au><au>Iwai, Tomoaki</au><au>Kabei, Kazuya</au><au>Nishide, Shunji</au><au>Maeda, Keiko</au><au>Kumada, Norihiko</au><au>Uchida, Junji</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hyperpolypharmacy and Frailty in Kidney Transplant Recipients</atitle><jtitle>Transplantation proceedings</jtitle><addtitle>Transplant Proc</addtitle><date>2022-03</date><risdate>2022</risdate><volume>54</volume><issue>2</issue><spage>367</spage><epage>373</epage><pages>367-373</pages><issn>0041-1345</issn><eissn>1873-2623</eissn><abstract>Kidney transplant recipients (KTRs) take multiple medications including immunosuppressants every day. Although polypharmacy is associated with frailty, the situation remains unknown in KTRs. The aim of the present study is to investigate the association between hyperpolypharmacy and frailty in KTRs. This study was a single-center, cross-sectional investigation carried out on KTRs between August 2018 and February 2019 at Osaka City University Hospital. Frailty was evaluated using the Kihon Checklist (KCL). The number of medications was determined from the regular medicines the participants took by mouth every day. Hyperpolypharmacy was defined as 10 or more medications. Statistical analyses were performed using multivariable logistic regression analyses and multivariable linear regression analyses. Of 211 KTRs enrolled in this study, the mean (SD) number of medicines taken orally regularly was 9.4 (3.4), and hyperpolypharmacy participants accounted for 41%. Hyperpolypharmacy was associated with both the total KCL score (odds ratio, 1.13; P = .016) and being frail compared with being robust (odds ratio, 5.70; P = .007) after adjustments for age, sex, and body mass index. The number of medications was associated with both the total KCL score (β = 0.20; P &lt; .001) and being frail compared with being robust (β = 2.51; P &lt; .001) after adjustments for age, sex, body mass index, dialysis vintage, time after transplant, serum albumin, and estimated glomerular filtration rate. The optimal cutoff value for the number of medications to detect frailty was 12 (area under the curve, 0.81). In KTRs, hyperpolypharmacy was prevalent and was associated with frailty.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>35033367</pmid><doi>10.1016/j.transproceed.2021.11.026</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-0245-2994</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0041-1345
ispartof Transplantation proceedings, 2022-03, Vol.54 (2), p.367-373
issn 0041-1345
1873-2623
language eng
recordid cdi_proquest_miscellaneous_2620753493
source MEDLINE; Elsevier ScienceDirect Journals
subjects Cross-Sectional Studies
Frailty - diagnosis
Humans
Kidney Transplantation - adverse effects
Polypharmacy
Renal Dialysis
Transplant Recipients
title Hyperpolypharmacy and Frailty in Kidney Transplant Recipients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T12%3A57%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hyperpolypharmacy%20and%20Frailty%20in%20Kidney%20Transplant%20Recipients&rft.jtitle=Transplantation%20proceedings&rft.au=Kosoku,%20Akihiro&rft.date=2022-03&rft.volume=54&rft.issue=2&rft.spage=367&rft.epage=373&rft.pages=367-373&rft.issn=0041-1345&rft.eissn=1873-2623&rft_id=info:doi/10.1016/j.transproceed.2021.11.026&rft_dat=%3Cproquest_cross%3E2620753493%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2620753493&rft_id=info:pmid/35033367&rft_els_id=S0041134521009325&rfr_iscdi=true